Serotonin vs The Joint Chiropractic

Serotonin tempts with velocity and open terrain. That 33% unit growth, fresh 2026 FDD, and approved-supplier procurement model are the classic early-stage tailwinds. But the math collapses under scrutiny. Eleven total units—eight franchised—nets a total addressable market of at most 11 accounts, and the investment floor at $905K means every deal is a capital-intensive slog. You’re not selling into a chain; you’re selling into a handful of well-funded operators who’ve yet to prove they can scale. The procurement model is theoretically favorable, but with only eight franchisees, the buyer pool is so shallow that a single “no” from the franchisor effectively kills the vertical.

The Joint Chiropractic gives you volume, budget, and urgency. With 935 units, 800 of them franchised, you’re looking at a real pipeline—churn alone at 12% unit growth delivers steady replacement demand. Average unit revenue at $615K means operators have the P&L to absorb software spend without the punitive cost of sale Serotonin’s $1.8M high-end buildout imposes. The catch is the franchisor_controlled procurement model and an overdue FDD, which means you’re selling through a gatekeeper and into a brand that’s operationally behind on compliance. That’s a tactical problem, not a strategic one: navigate the corporate relationship once and you unlock 800 buyers. Serotonin offers no such unlock.

The tradeoff is timing versus territory. Serotonin bets on getting in early with a brand that might become a category winner, but the absolute TAM is too small to matter. The Joint Chiropractic lets you monetize a large, revenue-stable base right now, with the procurement friction being a solvable gate, not a wall. In B2B franchise software, installed base beats growth rate.

Verdict: The Joint Chiropractic wins on total addressable market, unit economics, and immediate revenue opportunity despite the procurement hurdle.